CVRx to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call on January 25th, 2024
MINNEAPOLIS, Jan. 11, 2024 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ:CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release fourth quarter 2023 financial and operating results after market close on Thursday, January 25th, 2024. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day.
Related news for (CVRX)
- CVRx Announces Positive News on Outpatient Payment for Barostim
- 24/7 Market News Snapshot 16 July, 2025 – CVRx, Inc. Common Stock (NASDAQ:CVRX)
- CVRx Reports Preliminary First Quarter 2025 Financial Results
- CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2024 Financial Results and Issues Fiscal 2025 Guidance
- CVRx Announces Positive Outpatient Payment for Barostim Procedure in 2025